Response from CGB, page-83

And understand, yes been frustrating but
We are in transformation and onto be a major force in the MM
market
We have spread our tentacles and covering our basis , agreements/alliances
acquisition of MCL , that is generating revenue
Canntab , pharmocan , fast tracking revenue for Asian and other
Markets
Rather tie up funds that will pull in the $bucks bunny
Medcan as far as I am concerned are still on side
Hoping that the details of that commercial agreement
Is released soon